{
  "emaEpar": [],
  "fdaDrugLabel": [],
  "id": "Bavituximab",
  "nciThesaurus": {
    "casRegistry": "648904-28-3",
    "chebiId": "",
    "chemicalFormula": "",
    "definition": "A chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. Bavituximab binds to anionic phospholipids in a beta 2-glycoprotein I-dependent manner, inhibiting tumor growth by stimulating antibody-dependent cellular cytotoxicity (ADCC) to tumor vessels.",
    "fdaUniiCode": "Q16CT95N25",
    "identifier": "C49088",
    "preferredName": "Bavituximab",
    "semanticType": "Pharmacologic Substance",
    "subclassOf": [
      "C129822",
      "C20401"
    ],
    "synonyms": [
      "BAVITUXIMAB",
      "Bavituximab",
      "Chimeric Anti-Phosphotidylserine Monoclonal Antibody",
      "Tarvacin"
    ]
  }
}